BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Drug Development

  LimmaTech Biologics Expands Vaccine Pipeline by Licensing AbVacc’s Innovative Vaccine Candidate Against Staphylococcus aureus

  LimmaTech Biologics and AbVacc announced a license agreement that grants LimmaTech the exclusive rights to further develop AbVacc’s multivalent toxoid vaccine candidate, LBT-SA7, designed to prevent infections caused by the bacterial pathogen, Staphylococcus aureus.

  December 19, 2023

   · 

  6 min read
• Drug Development

  NanOlogy Clinical and Preclinical Immune Data Presented at NACLC and SITC

  NanOlogy LLC, a clinical-stage oncology company, reports data presented as posters during recent oncology conferences.

  December 19, 2023

   · 

  3 min read
• Drug Development

  TFF Pharmaceuticals Announces Positive Initial Data from Ongoing Phase 2 Trials of TFF VORI and TFF TAC

  TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) today announced positive initial data from the Company’s ongoing Phase 2 trials of TFF VORI and TFF TAC, along with clinical data from the ongoing TFF VORI Expanded Access Program (EAP).

  December 19, 2023

   · 

  10 min read
• Opthea Receives A$8.8 million R&D Tax Incentive

  Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced that it has received an A$8.8 million research and development tax credit from the Australian Taxation Office.

  December 19, 2023

   · 

  2 min read
• Business

  Appointment of Chief Business Officer

  19 December 2023 Avacta Group plc (“Avacta” or “the Group” or “the Company”) Appointment of Chief Business Officer.

  December 19, 2023

   · 

  4 min read
• Treace to Present at 42nd Annual J.P. Morgan Healthcare ConferenceTuesday, January 9, 2024, at 3:45 pm Pacific Time

  Treace Medical Concepts, Inc. today announced that John T. Treace, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024.

  December 19, 2023

   · 

  2 min read